Sesen Bio Inc

Sesen Bio — Corporate Update (March 2021)

84 slides from Sesen Bio's corporate update, Mar 15, 2021

  1. Slide 1: March 2021 Business Update

    NASDAQ: SESN March 2021 Business Update March 15, 2021

  2. Slide 2: Forward-Looking Statements

    2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical dev

  3. Slide 3: Corporate Highlights: Key Announcements over the Last 90 Days

    3 Corporate Highlights Key Announcements over the Last 90 Days  Signed OUS deal with Hikma for the MENA region  Completed analytical comparability package  Signed framework agreement with Qilu as additional CMO  Advanced partnership with LUMC  Completed EMA pre-submission activities  Favorable

  4. Slide 4: Clinical Perspective: Neal Shore, MD

    4 Clinical Perspective Vicineum for BCG-Unresponsive NMIBC • Medical Director, Carolina Urologic Research Center • Practicing physician with Atlantic Urology Clinics in Myrtle Beach, SC • National Urology Research Director for 21st Century Oncology • Conducted more than 350 clinical trials including

  5. Slide 5: Additional Disclosures

    5 Additional Disclosures • Dr. Shore is a paid consultant for Sesen Bio as well as the following companies: • Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, FerGene, Foundation Medicine, GConcology, Invitae, Janssen, MDxhealth, Merck,

  6. Slide 6: Clinical Perspective

    CLINICAL PERSPECTIVE Nea l Shore , MD, FACS

  7. Slide 7: The Patient Journey Is Guided by the Urologist

    BLOOD IN URINE Begin tests Cytology DIAGNOSIS BCG Testing Urologist visit UROLOGIST MAKES TREATMENT CHOICE Bladder removal See blood in urine; try different antibiotic See PCP; therapeutic trial of antibiotics prescribed BCG has failed TURBT Cystoscopy Bladder MRI CT Scan BCG Testing BCG again BCG a

  8. Slide 8: Vicineum has a Highly Differentiated Mechanism of Action

    8 T cells recognize neoantigen and kill cancer cells T cell proliferation DAMPs Neoantigen release Vicineum causes immunogenic cell death by triggering damage-associated molecular patterns (DAMPs) Vicineum selectively targets EpCAM on cancer cells while generally leaving healthy cells alone Vicineum

  9. Slide 9: Vicineum has a Compelling Benefit-Risk Profile

    9 Neal Shore, MD Clinical PerspectiveVicineum has a Compelling Benefit-Risk Profile *As referenced in FDA NMIBC Guidance for Industry, February 2018. Source: Phase III data as of the May 29, 2019 data cut. For additional information regarding Phase III clinical trial data please refer to slides 42-5

  10. Slide 10: Vicineum is bladder-sparing by delaying or avoiding cystectomy

    10 Phase III data suggests Vicineum is bladder-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery  Self-controlled storage organ in the body  Holds urine for release so the body is not exposed to harmful

  11. Slide 11: Time to Cystectomy: 88% Cystectomy-Free at 3 Years for Responders

    11 Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment Time to cystectomy: defined as the time from the date of first dose of study treatment to surgical bladder removal. Data consist of patients from all cohorts (n=133). % o f P at ie

  12. Slide 12: Complete and Partial Response in Phase II

    12 Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response Start of Treatment with Vicineum 3-Month Response 40% of patients had a complete response 43% of patients had a partial response 17% of patients had no response *Note: Data are from P

  13. Slide 13: Duration of Response

    13Duration of response: defined as the time from complete response to treatment failure. *Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Duration of Response: The longer you have a complete response, the higher the probability of remaining cancer-free 17% 42% 56% 61% 7

  14. Slide 14: Safety and Tolerability: Phase II and Phase III

    14 Safety and Tolerability: Phase II and Phase III clinical trials are highly consistent for safety and tolerability Category Phase II Patients (%) Phase III Patients (%) Any AE 43 (94%) 117 (88%) Grade 3-5 AEs 9 (20%) 29 (22%) Treatment-related AEs 30 (65%) 66 (50%) Treatment-related Grade 3-5 AEs

  15. Slide 15: Favorable Cost-Effectiveness Profile Based on ICER Report

    15 Neal Shore, MD Clinical Perspective Favorable Cost-Effectiveness Profile for Vicineum Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER) Overview: • ICER is the leading Health Technology Assessment body in the United States, and is an independent no

  16. Slide 16: Vicineum vs Keytruda Registration Trial Profile

    16 Vicineum Profile Registration Trial Keytruda Profile Registration Trial Key Patient Criteria • Failed BCG (5+2) • CIS +/- Ta/T1 • All comers • Failed BCG (5+2) • CIS +/- Ta/T1 • Ineligible or refuse cystectomy Efficacy N=89 N=102 Complete Response Rate At 3 Months At 12 Months At 18 Months 40% (C

  17. Slide 17: Financial Overview

    FINANCIAL OVERVIEW Monic a Forbe s

  18. Slide 18: Commercial Strategy Supports World-Class US Launch

    18 • Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after approval and launch • Urologists who treat NMIBC indicate a preference for Vicineum vs. Keytruda • Highly concentrated US market of ~1,500 Urologists treating

  19. Slide 19: OUS Opportunity Roughly Double the US

    19 We Estimate the OUS Opportunity for Vicineum is Roughly Double the US Significant Progress in Top 4 Markets Geography Peak Year Revenue Opportunity for Vicineum (captures 80% of variance) Europe $450M - $1,125M United States* $423M - $942M MENA $158M - $420M China $155M - $418M Rest of Asia (incl

  20. Slide 20: Financial Highlights

    20 Financial Highlights Strengthening the Balance Sheet while Minimizing Dilution YE 2020 Feb 2021 % Change Cash and cash equivalents $55M1 $98M2 +77% Stock price $1.35 $2.72 +101% Market cap $190M $451M +137% • No outstanding debt • Strengthened the balance sheet via prudent use of the ATM facility

  21. Slide 21: Sesen Quarterly Cash Balances

    21 Sesen Quarterly Cash Balances Steadily Building Cash Balance to Support Commercial Launch Phase $M $9.6 $13.9 $11.1 $13.3 $4.8 $18.2 $24.5 $56.1 $37.7 $42.0 $55.4 $98.2 0 20 40 60 80 100 120 2Q 20 3Q 20 4Q 20 Feb. 2021 Cash used in Operations Cash Raised Ending cash 1Amount includes cash, cash eq

  22. Slide 22: 2021 Annual Meeting Proxy Matters

    22 Sesen Bio 2021 Annual Meeting of Stockholders P roxy Matters– Designed to Align with 2021 Proxy Advisory Guidelines ISS Glass Lewis Increase the number of authorized shares by 200M   Increase number of shares for Employee Incentive Plan by 12M   Increase number of shares for Employee Stock Pu

  23. Slide 23: Corporate Overview

    CORPORATE OVERVIEW Thomas Canne l l , DVM

  24. Slide 24: Forward-Looking Timeline for Vicineum

    24 4Q 20 1Q 21 2Q 21 3Q 21 4Q 21 2Q 221Q 22 Positive progress in the US and Europe enables a clear regulatory path forward with the following anticipated milestones: BLA completion BLA=Biologics License Application; MAA=Marketing Authorization Application; HTA=Health Technology Assessment; NICE=Nati

  25. Slide 25: Brand Strategy

    25 Brand Strategy: To position Vicineum as the “Best in Class” which improves patient outcomes while reducing overall healthcare costs* Brand Goal: Market leadership in NMIBC in 2022 Brand Forecast: Peak global sales of $1B - $3B *For patients with BCG-unresponsive non-muscle invasive bladder cancer

  26. Slide 26: Pipeline of Targeted Therapies

    26 Pipeline of Targeted Therapies We Will Steadily Progress into Business Adjacencies Core BCG-unresponsive NMIBC Adjacent Less-than-adequate BCG Combo Therapy with CI First-line, high-risk NMIBC Transformational Head and Neck Cancer Imaging Agent VB6-845d (deBouganin) IL-6 Partnership W h er e to P

  27. Slide 27: March 2021 Business Update Key Takeaways

    27 MA RCH 2021 B US IN ESS UPDATE 1. Vicineum has the potential to improve patient outcomes while reducing overall healthcare costs 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Vicineum has the potential to be best- in-class with projected global peak r

  28. Slide 28: Thank You

    THANK YOU

  29. Slide 29: Talented and Experienced Leadership Team

    29 Thomas Cannell, DVM President, CEO and Director Glen MacDonald, Ph.D. Chief Technology Officer Mark Sullivan General Counsel and Corporate Secretary Erin Clark Vice President, Corporate Strategy and Investor Relations Monica Forbes Chief Financial Officer Omar Rifi Vice President, Business Develo

  30. Slide 30: Appendix - Table of Contents

    30 Appendix - Table of Contents Section Slide number Unmet Medical Need 31-34 Dual Mechanism of Action 35-37 Regulatory 38-41 Clinical Data 42-58 Commercial Opportunity 59-76 Manufacturing & Supply Chain 77-82 Intellectual Property 83-84 For investor purposes only, not intended for promotional purpo

  31. Slide 31: Unmet Medical Need

    31 Unmet Medical Need Appendix

  32. Slide 32: Significant Unmet Medical Need in NMIBC

    32 BCG ~440,000 new cases each year globally1 is complicating patient care Significant Unmet Medical Need in NMIBC 1Bray F et al. CA Cancer J Clin, 2018. 2Anastasiadis et al. Therapeutic Advances in Urology, 2012. 3Siegel et al. CA Cancer J Clin, 2019. 4Svatek RS, et al. Eur Oncol. 2014. 5Office of

  33. Slide 33: Significant Unmet Need for Patients with Bladder Cancer

    33 There is a Significant Unmet Need for Patients with Bladder Cancer with Limited Treatment Options Available Common Types of Cancer Estimated New Cases 2020 Estimated Deaths 2020 1. Breast Cancer (Female) 276,480 42,690 2. Lung and Bronchus Cancer 228,820 135,720 3. Prostate Cancer 191,930 33,330

  34. Slide 34: NMIBC Therapeutics Plagued by Manufacturing Issues

    34 NMIBC Therapeutics Have Been Plagued by Manufacturing Issues 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sanofi suspends production of BCG Connaught strain during facility renovations Merck announces shortages of BCG Tice strain Sanofi discontinues all global production of BCG Connaught strain M

  35. Slide 35: Dual Mechanism of Action

    35 Dual Mechanism of Action Appendix

  36. Slide 36: Highly Differentiated Dual Mechanism of Action

    36 Vicineum has a Highly Differentiated Dual Mechanism of Action (MoA) An Important Advancement in the Category of Precision Oncology • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets

  37. Slide 37: Evidence of Immune System Activation

    37 A f t e r 4 w k s o n t r e a t m e n t P r e - t r e a t m e n t PAT I E N T A : PAT I E N T B : Injected Tumor Injected Tumor Non-Injected Tumor Pre-clinical and Phase I Trial in SCCHN shows evidence of activation of patients’ immune systems Clinical Evidence (as seen in Phase I) Pre-Clinical E

  38. Slide 38: Regulatory

    38 Regulatory Appendix

  39. Slide 39: FDA Guidance for BCG-Unresponsive NMIBC

    39Source: FDA Guidance: BCG-Unresponsive Non-muscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry, February 2018. CRR, Complete Response Rate; DoR, Duration of Response; BCG, bacillus Calmette-Guérin; WHO, World Health Organization. 39 • Conduct nonclini

  40. Slide 40: BLA Finalized and Submitted to the FDA

    40 BLA Finalized and Submitted to the FDA on December 18, 2020 Positive Analytical Comparability Data Led to BLA Completion  General corporate information  Patent information and exclusivity  Waivers  Draft Label  Risk management plan  Draft carton and container labels  24 Non-clinical studie

  41. Slide 41: Completion of Vicineum BLA Submission

    41 Completion of Vicineum BLA Submission in December 2020 Sources: FDA applications for oncology products 2006 – 2015. Thomas D.W. et al., Clinical development success rates 2006-2015. 2016. Bio, BioMedTracker and Amplion. Phase Probability of Approval Products at end of Phase I 5% Products at end o

  42. Slide 42: Clinical Data

    42 Clinical Data Appendix

  43. Slide 43: Strong Benefit-Risk Profile in Phase III Trial

    43 : Vicineum demonstrates a strong benefit-risk profile in our Phase III Trial Benefit Risk Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkpoint inhibitors No dose or age-related increase in AEs Intrav

  44. Slide 44: Phase III Trial: Patient Demographics

    44 Phase III Trial: Patient Demographics TURBT: transurethral resection of bladder tumor Note: Data are as of May 29, 2019 data cut CHARACTERISTICS COHORT 1 COHORT 2 COHORT 3 CIS that was refractory or recurred within 6 months of adequate BCG CIS that recurred >6 months but ≤11 months of adequate BC

  45. Slide 45: Compelling Clinical Data Set

    45 Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) Primary Endpoint CIS patients Defined as the proportion of patients who show no evidence of high-risk disease, or disease progression (e.g., T2 or more advanced disease). • 40% CRR at 3 months • Lo

  46. Slide 46: Duration of Response

    46 Duration of response: defined as the time of complete response to treatment failure. *Not Estimable, the upper bound for the 95% confidence interval has not reached the median. **Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Median duration of response for th

  47. Slide 47: Duration of Response by BCG Exposure

    47 Duration of Response: Vicineum is generally more efficacious in CIS patients treated with less BCG Duration of response: defined as the time of complete response to treatment failure. *Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. The BCG shortage may cause a

  48. Slide 48: Time to Disease Recurrence

    48 Time to Disease Recurrence: Time to Disease Recurrence: 50% of high-risk papillary patients who were treated with Vicineum are disease-free at 1 year Time to disease recurrence: defined as the time from the date of the first dose of study treatment to treatment failure. Median time to disease rec

  49. Slide 49: Time to Cystectomy vs Currently Available Agents

    49 2018 FDA Guidance: The goal of therapy in patients with BCG-unresponsive NMIBC is to avoid cystectomy. % o f P at ie nt s C ys te ct o m y- Fr ee Median 3 6 9 12 15 18 21 240 27 30 33 Time from start of treatment (months) KM Estimate Censored 95% CI X Legend: No patient on treatment progressed to

  50. Slide 50: Overall Survival

    50 Overall Survival 1- and 2-year survival rates of patients on trial are comparable to those of the general population of similar age and gender demographics (predominantly male in their 70s) 1U.S. Social Security Administration Actuarial Life Table (https://www.ssa.gov/oact/STATS/table4c6.html), B

  51. Slide 51: Additional Clinical Data: Phase II vs Phase III CRR

    51 Additional Vicineum Clinical Data Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%- 51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-months 18% (8%-32%) 21%

  52. Slide 52: Evaluable Patient Data Tables for CIS Cohorts

    52 Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 12-months n=82 1

  53. Slide 53: Recurrence-free Rate in Papillary Patients

    53 Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence-free (RF) Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3-months n=38 71% (54%-85%) 6-months n=38 58% (41%-74%) 9-months n=38 45% (29%-62%) 12-month

  54. Slide 54: No Age-Related Increase in Adverse Events

    54 M ea n A E s/ pa tie nt 0 2 4 6 8 10 Safety and Tolerability: No age-related increase in adverse events in our Phase III trial Note: Data consist of patients from all cohorts (n=133). Mean AEs for all patients: 8.1 (range 0-54), Mean treatment-related AEs for all patients: 2.2 (range 0-51). Adver

  55. Slide 55: Confidence Interval Above FDA Success Criterion

    55 Vicineum confidence interval above FDA success criterion based upon complete response of other agents in patients with Carcinoma in situ Please use caution when drawing comparisons across different clinical trials 2Data are as of May 29, 2019 data cut from the Phase III VISTA trial 3To demonstrat

  56. Slide 56: Head and Neck Cancer: Difficult-to-Treat

    HEAD AND NECK CANCER: Difficult-to-Treat & Dominated by Primary Tumor • Head and neck cancer affects >650,000 people worldwide; ~350,000 deaths each year1 • 90% are squamous cell carcinomas of the head and neck (SCCHN)1 - Two-thirds diagnosed with advanced disease and severe prognosis • High risk of

  57. Slide 57: Monotherapy Studies in Late-Stage SCCHN

    57 PHASE 1 TRIALS ASSESSING DAILY AND WEEKLY DOSES SUGGEST IMMUNE-DRIVEN RESPONSE • Anti-tumor activity of 43% on daily dose; 62% on weekly dose • Observed regression or complete resolution of non- injected tumors • 207 days mean overall survival for EpCAM-positive patients vs. 125 days for EpCAM-ne

  58. Slide 58: Partnership Opportunity with LUMC

    58 Partnership Opportunity with LUMC Further Supports the Targeting Specificity of Vicineum Gastric Cancer Colorectal Cancer Esophageal Cancer LUMC = Leiden University Medical Center, the university hospital affiliated with Leiden University. LUMC is a modern university medical center for research,

  59. Slide 59: Commercial Opportunity

    59 Commercial Opportunity Appendix For investor purposes only, not intended for promotional purposes

  60. Slide 60: Virtuous Cycle of Advocacy

    60 Virtuous Cycle: High possibility that all three key segments are advocates & take action Sources: Sesen Bio internal market research: Patient Journey Insights, Blue Print qualitative study May 2018, n=24; Sesen Market Opportunity, Monitor Deloitte qualitative and quantitative (n=34) study October

  61. Slide 61: Differentiated vs. Branded Agents in Urology

    61 Brand Logo Differentiated vs. branded agents in Urology TM For investor purposes only, not intended for promotional purposes

  62. Slide 62: Continuity of Care for Patients with NMIBC

    62 Treatment Protocol BCG Vicineum Checkpoint Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X Vicineum has the Potential to Provide Continuity of Care for Patients with NM

  63. Slide 63: Urologists Prefer Vicineum Profile

    63 5.4 8.2 8.2 8.6 5.2 6.2 3.4 5.8 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Efficacy Safety Ease of integration Interest in use of product A ve ra ge R at in g Vicineum Profile Keytruda Profile 2020 Market Research Results High Prescribing Urologists Prefer Vicineum Profile Source: Emerging trea

  64. Slide 64: Reasons Urologists Prefer Vicineum Profile

    64 1Q 2020 Market Research Results Reasons Urologists Prefer Vicineum Profile • Urologists strongly prefer to retain ownership of patient journey – High degree of reluctance to refer to Medical Oncologists – Fear of losing follow-up diagnostics with patient after treatment referral • Urologists perc

  65. Slide 65: Highly Concentrated Prescriber Base

    65 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 20 0 40 0 60 0 80 0 1, 00 0 1, 20 0 1, 40 0 1, 60 0 1, 80 0 2, 00 0 2, 20 0 2, 40 0 2, 60 0 2, 80 0 3, 00 0 3, 20 0 3, 40 0 3, 60 0 3, 80 0 4, 00 0 4, 20 0 4, 40 0 4, 60 0 4, 80 0 BCG Prescribers Highly Concentrated Prescriber Base Allows for Efficien

  66. Slide 66: Caregiver Digital and Social Strategy

    66 At treatment decision points, caregivers often play an influential role Our strategy is to educate and inform caregivers via a wide range of digital and social channels Digital • Paid search • Organic search • Videos • Banners • Website (branded or unbranded) Social • Facebook community groups •

  67. Slide 67: Pricing and Reimbursement

    67 Pricing and Reimbursement US Benchmarks Price Reference (Annual Cost) $200K $0K Sources: 1Center for Medicare and Medicaid Services (CMS) Average Selling Price (ASP) Price List as of 1Q 2020 (cms.gov). 2Payer Interviews, ClearView Analysis, n=10, March 2019. *Note: Payers cited a possibility of u

  68. Slide 68: Emerging Competitor Landscape

    68 Checkpoint Inhibitors: Keytruda • Approved for NMIBC January 2020 • Reimbursed at $175,000/year with minimal payer restrictions Tecentriq • Awaiting Phase III enrollment • Phase II closed prematurely as it failed to meet futility endpoint • Withdrew label for advanced Urothelial Carcinoma indicat

  69. Slide 69: Competitive Summary: BCG-Unresponsive NMIBC Therapies

    69  Competitive Summary: BCG-Unresponsive NMIBC therapies Report CR rate at discrete timepoints Patient failures taken off therapy Local and Central review of pathology BCG + N-803 BCG in combo with rIL-15 Vicineum Fusion Protein (Dual MOA) Keytruda Checkpoint Inhibitor Adstiladrin Gene Therapy Tre

  70. Slide 70: Sesen Bio OUS Strategy Overview

    70 Sesen Bio OUS Strategy Overview • Vicineum is a product with potential for registration and reimbursement in multiple developed markets • OUS opportunity for Vicineum is 2-3 times larger than the US • Efficient process to manage strong, engaged relationships with key partners worldwide • Partner

  71. Slide 71: Partnership Opportunity in China: Qilu Pharmaceutical

    71 Partnership Opportunity in China: Qilu Pharmaceutical Profile • Top 10 Pharmaceutical Company in China with >$3B in annual revenue • Extensive clinical experience • 2nd largest clinical team in Chinese Big Pharma • Focused on biosimilar and innovative drugs, with nearly 40 years of clinical devel

  72. Slide 72: Overview of Qilu License Agreement

    72 Overview of Qilu License Agreement • Financial terms include significant sources of non-dilutive capital • Upfront payment of $12M in cash • Eligibility to receive up to $23M in regulatory and tech transfer milestones in addition to 12% royalties on net sales for at least 12 years • Qilu will be

  73. Slide 73: Milestones Achieved through Qilu Partnership

    73 Significant Milestones Achieved through Qilu Pharmaceutical Partnership Overview of Key Progress • $12M upfront received on September 29, 2020 • CMO framework agreement signed on December 4, 2020 • Helps to ensure reliable global supply and creates opportunity for a reduction in COGS • $3M milest

  74. Slide 74: Key Partnership with Hikma in MENA

    74 Key partnership with leading partner in MENA Hikma Pharmaceuticals Profile • Multi-national pharma company specializing in the development and commercialization of a broad range of high-quality medicines across the US, MENA and Europe • Public company headquartered in London with a market cap of

  75. Slide 75: Simulation Inputs: US Market

    75 Simulation Inputs: US Market Estimated patients eligible for branded therapy1 (Annual high-risk NMIBC patients unresponsive to BCG) Lower Bound 7,800 patients Upper Bound 20,400 patients Estimated peak market share2 (Likely share of branded agents) Approximate year 1 doses received3 (Percent of p

  76. Slide 76: Simulation Inputs: OUS Market

    76 Simulation Inputs: OUS Market Sources: Ferlay. Intern. J. Canc. 2015; UN World Population Reports; SEER; GLOBOCAN; RedBook; Lauertaxe; Ameli; NICE; Vademecum; AIFA; NHI; CADTH; ANVISA; CBiP; Danish Medicines Agency; The Pharmaceutical Benefits Scheme; Saudi Food & Drug Authority; South African Me

  77. Slide 77: Manufacturing & Supply Chain

    77 Manufacturing & Supply Chain Appendix

  78. Slide 78: Vicineum End-to-End Supply Chain

    78 Vicineum End-to-End Supply Chain World-class manufacturing and distribution capabilities ensure execution excellence • Vicineum Drug Substance manufacturer • 7 commercial products launched from site where Vicineum is manufactured o 3 produced via E. coli o 2 oncology products • 30+ years manufact

  79. Slide 79: Highly Reliable Manufacturing Process for Vicineum

    79 Highly Reliable Manufacturing Process for Vicineum Cell Bank 2000 L E. coli Production Bioreactor 5: Q-Sepharose HP 5 Column Purification Shake flask Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) DP Fill Finish (7 mL @ 5mg/mL)1: Q-Se

  80. Slide 80: Reliable and Inexpensive Manufacturing Process

    80 Reliable and Inexpensive Manufacturing Process • Vicineum is manufactured using a robust, industry-standard microbial expression system • The manufacturing process is highly reliable, reducing the risk of supply shortages • The manufacturing process is inexpensive, leading to a relatively low cos

  81. Slide 81: Commercial Manufacturing Strategy Based on Comparability

    81 Commercial Manufacturing Strategy Based on Demonstrating Comparability The analytical comparability plan is comprised of 4 key elements: 1. Analytical Release Testing • Assesses the purity, biological activity and general characteristics of Vicineum 2. Biophysical Characterization • Assesses the

  82. Slide 82: Meaningful Progress on Demonstrating Comparability

    82 Meaningful Progress on Demonstrating Comparability Indicates acceptance criteria met for batches used in clinical trials (Sesen) or technology transfer (FUJIFILM Diosynth Biotechnologies) Sesen FUJIFILM Diosynth Biotechnologies Test Phase III PPQ1 PPQ2 PPQ3 Appearance     pH     Identity

  83. Slide 83: Intellectual Property

    83 Intellectual Property Appendix

  84. Slide 84: Vicineum Patent Life

    84Note: Patent life assessment reflects independent analysis by Hogan Lovells US LLP. *Data exclusivity granted by FDA under the Biologics Price Competition and Innovation Act of 2009 (codified at 42 U.S.C. § 262(k)) Vicineum Patent Life Potential for 12 years of biologics marketing exclusivity from

Sesen Bio — Corporate Update (March 2021) on 6ix